NHLBI
Research and Policy Update
Number 15
March 2005
This
electronic distribution list will provide updates from the
NHLBI Web Site for the research community. The Updates will be
sent as needed, but no more than once a week.
Funding Updates
Please
Note: Links to RFAs and PAs will take you to the NIH
Web site
RFA-HL-05-010: Pediatric Heart Network
Receipt Dates: |
Letter of Intent, August 26, 2005 |
Application, September 23, 2005 |
RFA-HL-05-013:
Innovative Technologies for Engineering Small Blood Vessels
Receipt
Dates: |
Letter
of Intent, April 18, 2005 |
Application,
May 17, 2005 |
RFA-HL-05-003:
Heart Failure Clinical Research Network—Frequently
Asked Questions
RFA-HL-04-035:
Summer Institute Program to Increase Diversity in Health-Related Research
Receipt
Dates: |
Letter
of Intent, August 14, 2005 |
Application,
September 14, 2005 |
PAR-05-063:
Collaborations with National Centers for Biomedical Computing
(expires January 18, 2008)
PA-05-058: Lung Response to Inhaled Highly Toxic Chemicals
(expires February 28, 2008)
For
additional initiatives, please visit the following Web page:
NHLBI Grants and Contracts
page
Policy Updates
Model Organisms for Biomedical Research: NIH/NHLBI Policy on
Sharing Organisms and Related Resources
For
additional policy documents, please visit Funding
/ Award Policy section on the following Web
page:
Funding, Training, and Policies
Training Updates
NHLBI
NRSA T32 Supplemental Guidelines (updated)
Helpful
Hints for K24 Applicants (updated)
For
more information on training and career development programs,
please visit the following Web page:
Training and Career Development
Meetings
List
of upcoming meetings
National
Heart, Lung, and Blood Advisory Council Meeting, June 16,
2005
For
more information, and the most current list of upcoming meetings,
please visit the following Web page:
Announcements of NHLBI Meetings,
Conferences, and Events
Reports
of past meetings
Cerebrovascular
Biology and Disease, Working Group Summary, January 28, 2005
NIH
Conference on Dietary Supplements, Coagulation, and Antithrombotic
Therapies, Executive
Summary, January
13-14, 2005
Peripheral
Arterial Disease (PAD) Coalition: Inaugural Meeting Summary,
June 17, 2004
Healthy
Weight Community Outreach Initiative, Strategy Development Workshop
Report,
February 17-18, 2004
For more information
on past meetings, please visit the following Web page:
Workshop and Meeting Summaries,
and Other Scientific Reports
Press Releases
Statement
from Elizabeth G. Nabel, M.D., Director of the National Heart,
Lung, and Blood Institute of the National Institutes of Health
on the Findings of the Women's Health Study, March 7, 2005
For
additional Press Releases, please visit the following Web page:
Current Press Releases
Selected NHLBI Vacancies
The NHLBI has no
vacancies to highlight at this time.
Note:
There are often changes and additions, for the most current information,
please visit the NHLBI Jobs Opportunities
page
Other Items of Interest
NHLBI
Fact Book, Fiscal Year 2004
New
Datasets Available:
The Beta-Blocker
Heart Attack Trial (BHAT)
The Beta-Blocker Heart Attack Trial (BHAT) was a National Heart,
Lung, and Blood Institute-sponsored, multicenter, randomized,
double-blind, and placebo-controlled trial designed to test whether
the regular administration of propranolol hydrochloride to men
and women who had experienced at least one myocardial infarction
would result in a significant reduction in total mortality during
a two- to four-year period.
The Lipid Research
Clinics
The Lipid Research Clinics began under the sponsorship of the
National Heart, Lung, and Blood Institute, National Institutes
of Health. Part of this program was the Lipid Research Clinics
Prevalence Study, a standardized series of cross-sectional surveys
of various North American populations designed to determine the
prevalence of dyslipidemias and to describe the distributions
of lipids and lipoproteins in major ethnic and social groups.
The
Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT),
The LRC-CPPT was a multicenter, randomized, double-blind study,
designed to test the efficacy of cholesterol lowering in reducing
risk of coronary heart disease (CHD). The LRC-CPPT findings showed
that reducing total cholesterol by lowering LDL-C levels can diminish
the incidence of CHD morbidity and mortality in men at high risk
for CHD because of raised LDL-C levels. This clinical trial provided
strong evidence for a causal role for these lipids in the pathogenesis
of CHD (JAMA, 251(3), 351-64 (January 20, 1984).
An
Archive of the current and past issues
is available on the NHLBI Web site.
Two
ways to unsubscribe:
- Send an e-mail message to: LISTSERV@LIST.NIH.GOV
and, in the text of your message (not the subject line), write
(or copy/paste):
SIGNOFF NHLBI-RESEARCH-POLICY-L
- Use the List Web Page
A) select
this link
B) Enter your e-mail address as it appears in the To: field
of the list,
C) Enter your full name, and
D) Select the button, Leave the list.
|